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Abstract
Cellular activation, proliferation and survival in chronic inflammatory
diseases is regulated not only by engagement of signal trans-
duction pathways that modulate transcription factors required for
these processes, but also by epigenetic regulation of transcription
factor access to gene promoter regions. Histone acetyl trans-
ferases coordinate the recruitment and activation of transcription
factors with conformational changes in histones that allow gene
promoter exposure. Histone deacetylases (HDACs) counteract
histone acetyl transferase activity through the targeting of both
histones as well as nonhistone signal transduction proteins
important in inflammation. Numerous studies have indicated that
depressed HDAC activity in patients with inflammatory airway
diseases may contribute to local proinflammatory cytokine produc-
tion and diminish patient responses to corticosteroid treatment.
Recent observations that HDAC activity is depressed in rheuma-
toid arthritis patient synovial tissue have predicted that strategies
restoring HDAC function may be therapeutic in this disease as
well. Pharmacological inhibitors of HDAC activity, however, have
demonstrated potent therapeutic effects in animal models of
arthritis and other chronic inflammatory diseases. In the present
review we assess and reconcile these outwardly paradoxical study
results to provide a working model for how alterations in HDAC
activity may contribute to pathology in rheumatoid arthritis, and
highlight key questions to be answered in the preclinical evaluation
of compounds modulating these enzymes.
Introduction
Persistent recruitment, activation, retention and survival of
infiltrating immune cells in the synovium of patients with
rheumatoid arthritis (RA) and other forms of inflammatory
arthritis, stromal cell hyperplasia and eventual joint
destruction, are fueled and maintained by a complex network
of chemokines, cytokines, growth factors and cell–cell
interactions. Explosive increases in our understanding of how
distinct components of this network, such as TNFα, IL-1, IL-6
and receptor activator of NFκB ligand, contribute to
inflammation and joint destruction in RA have been translated
into innovative and increasingly successful treatment of
patients in the clinic [1]. Many of the extracellular stimuli
driving pathology in RA do so through the activation of con-
served intracellular signaling proteins and pathways, inclu-
ding NFκB, the mitogen-activated protein kinases, phospha-
tidylinositol 3 kinases (PI3Ks) and the Janus tyrosine kinase
(JAK)/signal transducers and activators of transcription
(STAT) pathway. These in turn represent additional targets for
therapeutic intervention to which intensive academic,
pharmaceutical and clinical effort is being applied [2]. The
relative utilization, contribution and requirement of specific
inflammatory mediators, and their intracellular signaling
pathways, in the pathology of RA, however, is quite hetero-
geneous between patients – possibly explained by predis-
posing genetic factors and environmental influences [3].
Inflammatory gene responses are further subjected to epi-
genetic regulation, most simply defined as inherited or
somatic modification of DNA that, rather than altering gene
product function, changes gene expression without altering
the sequence of bases in the DNA. Epigenetic modifications
important to gene regulation include methylation of DNA and
post-translational modification of histone proteins, which
regulate the chromatin architecture and gene promoter
access. Methylation of DNA, particularly of CpG dinucleo-
tides clustered in islands surrounding gene promoter regions,
can effectively silence gene expression by blocking trans-
cription factor binding to DNA, or activating transcriptional
co-repressors [4]. Changes in the methylation status of
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genes regulating cell proliferation, inflammatory responses and
tissue remodeling have been reported in RA, systemic sclerosis
and systemic lupus erythematosus, suggesting epigenetic
contributions to pathology in these diseases [5,6]. Post-
translational modifications to histone proteins, including acetyl-
ation, methylation, phosphorylation, sumoylation and ubiquitina-
tion, regulate transcription factor access to gene-encoding
regions of DNA and facilitate gene transcript elongation [7].
Recent evidence has suggested that decreased histone
deacetylase (HDAC) activity in RA patient synovial tissue may
relax the chromatin structure and promote pathology by
enhancing transcription of inflammatory gene products [8].
Current discussion has focused primarily on possible
epigenetic contributions of altered HDAC activity to the
pathology of RA and other immune-mediated inflammatory
diseases [5,6,9]. Little attention has been given, however, to
the potential role of HDACs in nonepigenetic processes,
such as the dynamic regulation of intracellular signaling
pathways in RA. In the present review, we shall briefly
introduce how reversible acetylation of histone and non-
histone proteins regulates gene expression, and how HDAC
inhibitors (HDACi) influence this process, and we highlight
key intracellular signal transduction pathways important to RA
that are regulated by reversible acetylation. We will then
critically review and reconcile paradoxical findings that, while
depressed HDAC activity is thought to contribute to human
immune-mediated inflammatory diseases, pharmacological
inhibitors of HDAC activity display potent therapeutic effects
in animal models of arthritis. In doing so, we provide a
framework for assessing the role of HDACs in RA, and the
therapeutic potential of modifying HDAC activity in the clinic.
Regulation of gene expression by reversible
acetylation
Regulation of gene expression is directly associated with
changes in the conformation of chromatin [10]. These
changes occur as a result of acetylation and deacetylation of
core histones, the major protein components of the chromatin
structure [10,11]. Two copies of each of four histone proteins
(H2A, H2B, H3 and H4) form a complex around which 146
base pairs of the DNA strand are wound. The N-terminal tail
of each histone contains several lysine residues, substrates
for enzymatic modification by the addition of an acetyl group.
Histone acetylation not only reduces the net positive charge
of the protein, promoting DNA unwinding and relaxation of
the chromatin structure, but also creates binding sites on the
histone for transcriptional cofactors and other cellular proteins
containing bromodomains [12]. Deacetylation of histone lysine
residues reverses this process, allowing condensation of the
nucleosome and preventing transcription factor and RNA
polymerase II access to gene promoters [7,10].
Reversible acetylation and deacetylation of histones is an
important process in the regulation of inflammatory gene
responses [11,13]. The acetylation status of histones is
regulated by two different classes of enzymes: histone acetyl
transferases (HATs) and HDACs. TNFα, lipopolysaccharide
and other inflammatory stimuli induce association of multiple
transcription factors, including the NFκB p65/RelA subunit,
activator protein 1, p53 and forkhead box class O (FoxO)
proteins, with transcriptional coactivators containing intrinsic
HAT activity (Figure 1) [14].
Transcription factor association with HATs, such as p300,
cAMP-response element-binding protein-binding protein
(CBP) or P/CAF, accomplishes three tasks important in the
regulation of gene induction (Figure 1) [10]. First, transcrip-
tion factor association with HATs targets HAT enzymatic
activity to gene promoter regions. Second, the recruited HAT
activity induces histone acetylation and exposure of gene
promoter regions. Third, HATs acetylate the associated
Figure 1
Epigenetic and signal transduction contributions of histone
deacetylase activity to gene transcription and cell biology. (1) Ligation
of cytokine or other inflammatory receptors leads to phosphorylation
and/or dimerization of transcription factors (TF), followed by their
nuclear translocation and association with histone acetyl transferases
(HATs). (2) Subsequent activation of HATs contributes to epigenetic
regulation of gene expression through acetylation (Ac) of histones
(barrels), relaxing chromatin structure, and (3) exposing gene promoter
regions to the TF. Histone deacetylases (HDACs) reverse this
epigenetic process, leading to chromatin condensation and repression
of gene expression. HATs and HDACs also finely tune gene
expression and cellular processes through pleiotropic, nonepigenetic
signaling pathways. Sequential acetylation and deacetylation of
specific lysine residues on TF – such as signal transducers and
activators of transcription (STAT), NFκB p65 and forkhead box class O
proteins – in the nucleus or cytoplasm, influence TF protein stability,
nuclear localization, DNA binding capacity, activation and gene target
specificity. (4) Depending on the transcription factor and gene target,
this can either enhance or inhibit gene transcription.Page 3 of 13
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transcription factor – this can modify the protein half-life of
the transcription factor, regulate its nuclear retention and
modulate its transcriptional activity [11].
In the simplest of models, the enzymatic activity of HDACs
opposes that of HATs, repressing gene transcription through
deacetylation of histones, and repressing activation of trans-
cription factors via deacetylation or recruitment of trans-
criptional co-repressors, such as glucocorticoid receptors
[11,15]. For many transcription factors, however, including
NFκB p65 and FoxO proteins, sequential acetylation and
deacetylation of lysines on transcription factors is also
required for stabilizing expression, or activating or
determining the target gene specificity of the transcription
factor (Figure 1) [14]. HATs and HDACs therefore do not
function simply as on/off switches for gene transcription.
Instead, a coordinated balance in their activity is required for
the functional output of transcription factors.
Histone deacetylases and histone
deacetylase inhibitors
The human genome encodes 18 different HDACs, which are
grouped into four distinct classes based on structural
homology with HDACs found in yeast [11,16]. Class I
HDACs (HDAC1 to HDAC3 and HDAC8) are nuclear
proteins broadly expressed throughout mammalian tissues
and most closely resemble yeast RPD3. Class II HDACs
(HDAC4 to HDAC7, HDAC9 and HDAC10), most similar to
yeast HDA1, display a more restricted tissue expression and
can shuttle between the nucleus and cytoplasm, exerting their
effects on targets in both cellular compartments. HDAC11 is
designated as the sole class IV HDAC, due to low sequence
similarity with other HDACs [16]. Class III silent information
regulator 2 (sirtuin) HDACs (Sirt1 to Sirt7) are nicotinamide
adenosine dinucleotide-dependent enzymes, structurally un-
related to class I, class II and class IV HDACs. Of the sirtuins,
only Sirt1 displays strong deacetylase activity, while the
others have unknown functions or act as mono-ADP-ribosyl
transferases. Sirt1, like other HDACs, targets both histone
and nonhistone proteins [17,18].
HDACi, both synthetic and naturally derived, can be grouped
loosely into four categories based on their chemical
structures [16,19]. Well-characterized hydroxamic acid
derivatives include Trichostatin A (TSA), suberoyl anilide
bishydroxamide (SAHA, vorinostat), and ITF2357. Butyrates
and valproic acid are short-chain fatty acids, HC-toxin and
FK228 (depsipeptide, also known as FR901228 in earlier
studies) are cyclic tetrapeptides/epoxides, and MS-275 is a
benzamide derivative. In vitro these compounds inhibit HDAC
activity at concentrations ranging from nanomolar (TSA,
ITF2357, HC-toxin) to millimolar (butyrates, valproic acid).
The hydroxamates are nonspecific in the sense that they do
not discriminate between distinct class I, class II and class IV
HDACs. In contrast, valproic acid and MS-275 selectively
target class I HDACs at lower concentrations, while also
inhibiting class II HDACs at higher concentrations [16,19,20].
Knowledge of the crystal structure of HDACi bound to
HDACs, as well as the development of strategies allowing
high-throughput analysis of chemical libraries, is leading to
the generation of new HDACi and the potential identification
of HDAC isoform-specific inhibitors. One novel compound
identified by this strategy is tubacin, a specific inhibitor of
HDAC6 [21]. Sirtuins, as well as other nicotinamide
adenosine dinucleotide-dependent enzymes, are inhibited by
nicotinamide. A growing list of sirtuin inhibitors, including
sirtinol, is being identified through biochemical screens [22],
but their influence on cellular biology or gene responses
relevant to inflammatory disease is just beginning to be
assessed [23].
Many of the compounds listed above are in phase I, phase II
and phase III clinical trials for the treatment of leukemias and
solid tumors [16,19,20,24]. In general, cancer cells are more
sensitive to HDACi than their nontransformed cellular
counterparts, these compounds have been well tolerated by
patients, and therapeutic effects have been documented.
Most HDACi have been shown to induce cell cycle arrest,
differentiation and/or apoptosis in a wide range of
transformed cells in vitro, in animal tumor models and in
clinical cancer trials [19]. The ability of HDACi to induce
tumor growth arrest is predominantly associated with their
ability to induce expression of cyclin-dependent kinase
inhibitor p21Waf1. Apoptosis induction may be secondary to
cell cycle arrest, or may be a result of cell-specific regulation
of proapoptotic genes (Bak, Bax, Bim, Noxa, Puma and
TRAIL) and of antiapoptotic genes (IAPs, Mcl-1, Bcl-2,
Bcl-XL, and FLIP) [25,26].
Nonhistone targets of histone deacetylases
in RA
Several lines of experimental evidence make it increasingly
clear that the effects of HDACi on cellular activation,
proliferation and survival cannot be attributed solely to the
regulation of chromatin structure.
First, in cancer trials it has been difficult to establish a clear
association between HDACi pharmacokinetics and histone
acetylation [27,28]. Second, gene array profiles obtained
from cell lines exposed to different HDACi report that only
2% to 10% of expressed genes are regulated by HDACi, a
comparable number of which are upregulated and are
downregulated [26,29,30]. These findings are generally
incompatible with global chromatin opening being the primary
effect of HDACi exposure. Third, careful analysis of cellular
dose-responsiveness to HDACi has demonstrated regulation
of cytokine production in the absence of changes in histone
acetylation status [31]. Fourth, phylogenetic studies in
bacteria indicate that HDACs evolved prior to histones,
suggesting an initial role for HDACs in the regulation of
nonhistone substrates [32]. Fifth, a number of gene product
targets used as biomarkers for HDACi activity in vivo, such as
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direct substrates of HDACs. The acetylation status of these
transcription factors influences protein stability, activation and
gene promoter specificity.
Some 200 nonhistone proteins have been identified as
HDAC substrates, at least in vitro [14,19], and a subset of
these substrates has already been identified as playing an
important role in disease perpetuation and progression in RA
[2]. Studies addressing the acetylation status of signaling
proteins, and consequences of changes in protein acetylation
for cellular activation and survival in RA synovial tissue, may
define how depressed HDAC activity contributes to
pathology in RA, and may suggest molecular mechanisms
responsible for the therapeutic effects of HDACi in animal
models of arthritis.
Regulation of NFκ κB signaling
Components of the NFκB transcription factor are highly
expressed and activated in RA synovial tissue, making
significant contributions to inflammatory gene expression and
cellular survival in the synovium [2]. The NFκB p65/RelA
subunit is acetylated on at least five distinct lysine residues
by p300/CBP. Acetylation of lysine 221 weakens p65 affinity
for IκBα, allowing dissociation of p65 and subsequent
nuclear import [33]. This acetylation step also enhances p65
affinity for DNA, but a separate acetylation event at lysine 310
is required to enhance p65 transcriptional activity [34].
Acetylation of p65 at distal lysines 122 and 123 reciprocally
decreases the p65 binding affinity to DNA, enhances
association with IκBα, and promotes nuclear export of the
transcription factor [35]. HDAC1, HDAC2 and HDAC3 can
promote deacetylation of p65 at lysine 221, stabilizing
p65–IκBα interactions [33], while SIRT1 can inactivate p65
through deacetylation of lysine 310 [36].
Regulation of FoxO signaling
The human FoxO family of transcription factors consists of four
members: FoxO1, FoxO3a, FoxO4 and FoxO6. The PI3K-
responsive FoxO1, FoxO3a and FoxO4 proteins modulate the
expression of genes regulating cell cycling (for example,
p27Kip1 and p21Waf1), genes regulating stress responses (for
example, catalase and manganese superoxide dismutase) and
genes regulating apoptosis (for example, FasL, Bim, and
TRAIL) [37].
FoxO proteins integrate growth factor and stress stimuli
either to promote cell proliferation, growth arrest and survival
or to induce apoptosis [38]. Activation of the PI3K/protein
kinase B (PKB) pathway by growth factors and inflammatory
cytokines results in FoxO phosphorylation, subsequent
nuclear exclusion and a block in transcription of FoxO-
regulated genes. PI3K/PKB signaling is highly activated in RA
synovial tissue, and significantly elevated levels of PKB-
inactivated FoxO4 are present in RA synovial tissue macro-
phages compared with disease controls [39,40]. Curiously,
within RA patient populations, PKB-dependent inactivation of
FoxO1, FoxO3a and FoxO4 correlates inversely with patient
parameters of inflammatory disease activity (erythrocyte
sedimentation rate and serum C-reactive protein concentra-
tions) [40]. This might be explained by findings that oxidative
stress and proinflammatory cytokines counteract PI3K/PKB
signaling to drive nuclear localization, transcriptional activa-
tion and gene target specificity of FoxO proteins [38].
JNK-dependent phosphorylation of FoxO proteins, possibly in
conjunction with Mst-1-dependent phosphorylation, promotes
FoxO nuclear import [38]. In the nucleus, FoxO proteins can
undergo serial acetylation and deacetylation. Although details
are still emerging, it appears that acetylation of FoxO proteins
by p300/CBP can induce transcription of proapoptotic gene
products or, in the presence of sufficient PI3K/PKB signal,
facilitate FoxO nuclear export [41]. Sequential deacetylation
events mediated by class I/II HDACs and Sirt1, however,
target FoxO to transcribe genes needed for cell cycle arrest
and survival responses to environmental stress [38].
The ability of FoxO transcription factors to integrate multiple
signals to determine cell fate choices (proliferation, survival or
apoptosis) influencing inflammatory disease in vivo is
strikingly recapitulated in FoxO3a-deficient mice. Mice lack-
ing FoxO3a develop spontaneous systemic autoimmune
disease marked by proliferation and activation of autoimmune
T cells [42]. When these mice are crossed onto a Rag2–/–
background (lacking lymphocytes), however, the resulting
progeny are resistant to K/BxN serum-induced arthritis,
probably due to Fas-induced apoptosis of activated neutro-
phils [43]. Together, these studies provide circumstantial
evidence that FoxO proteins interpret contextual signals to
regulate inflammatory responses in vivo.
Regulation of tumor suppressor p53 signaling
The tumor suppressor protein p53 regulates cellular
responses to stress signals causing DNA damage.
Stabilization and transcriptional activation of p53 induces cell
cycle arrest at the G1/S interface, allowing for effective repair
of fragmented DNA. When the extent of DNA damage is
broad, cells undergo p53-induced apoptosis [2].
In RA, high levels of fragmented DNA are detected in synovial
tissue, and increased protein expression of p53 is often
observed, primarily in late stages of the disease [44]. The
enhanced protein expression of p53 might be explained by
reactive oxygen species-induced somatic mutations in p53
[45]. Some of these mutations lead to the expression and
accumulation of inactive p53, which could in turn contribute
to inadequate apoptotic responses of stromal cells in the
inflamed joint [46]. The p53 protein half-life and activation,
however, is tightly regulated by multiple reversible phos-
phorylation, methylation, ubiquination and acetylation events,
which could also contribute to altered p53 protein expression
and function in RA synovial tissue [47].
Arthritis Research & Therapy    Vol 10 No 5 Grabiec et al.
Page 4 of 13
(page number not for citation purposes)Acetylation of p53 by p300/CBP or P/CAF can increase p53
protein stability in vitro, by blocking Mdm2-mediated
ubiquitination and proteasomal degradation of p53. Acetyla-
tion of p53 is reversed by Sirt1, inhibiting p53 transcriptional
activity and facilitating its degradation [48]. Association of
p53 with HATs can also result in transactivation of p53,
although additional mutational and genetic studies have cast
doubt on how and whether acetylation regulates p53 stability
or activity in vivo [47]. Given the potent effects of p53 on
fibroblast-like synoviocyte (FLS) proliferation and survival in
vitro, it will be of interest to determine whether acetylation
also regulates the function of p53 in RA synovial tissue.
Regulation of JAK/STAT signaling pathways
Activation of JAK kinases and subsequent stimulation of
transcriptional activity of the STAT family of transcription
factors is one of the main signaling pathways triggered by
cytokines. JAK/STAT signaling regulates expression of genes
involved in cellular activation, differentiation and survival [2].
In analyses of RA synovial tissue, increased expression and
activation of STAT1 is observed in RA patients compared
with disease control individuals [49]. Additionally, activation
of STAT3 contributes to the survival of RA synovial
macrophages. Inhibition of STAT3 induces apoptosis in
macrophages isolated from the joints of RA patients via
downregulation of the antiapoptotic protein Mcl-1 [50].
The regulation of gene expression by STATs requires HDAC
activity – TSA, SAHA and butyrate can block activation of
JAK1 and subsequent STAT1 phosphorylation in IFNγ-
stimulated carcinoma cells, and STAT1-dependent trans-
cription can be enhanced by overexpression of HDAC1,
HDAC2 or HDAC3 [51]. Also, the protective effects of SAHA
in a murine model of graft versus host disease are associated
with a block in the rapid accumulation of phosphorylated
STAT1 in the liver and the spleen [52]. While it appears that
acetylation may regulate STAT1 signaling indirectly, sub-
stantial evidence indicates that STAT3 is a direct target of
HATs and HDACs. STAT3 dimerization, DNA binding and
transcriptional activation following cytokine stimulation
requires p300/CBP-induced acetylation, and can be
negatively regulated by overexpression of HDACs – primarily
HDAC3 [53,54].
It is thus clear that reversible acetylation and deacetylation
play a central role in the function of intracellular signaling
proteins that regulate cellular activation and cytokine
production, proliferation and survival – key cellular themes in
the maintenance of chronic inflammation. As many of the
signaling proteins discussed above are known (or highly
suspected) to contribute to pathology in RA, it will be of
interest to determine the acetylation status of these proteins
in RA synovial tissue, and how modulation of HDAC activity
regulates signaling capacity. Given the pleiotropic effects that
acetylation can confer upon transcription factor function, as
evident with NFκB p65 and FoxO proteins, it will be critical to
distinguish between effects on DNA binding capacity,
transcriptional activity and gene target specificity.
Acetylation in human immune-mediated
inflammatory disease
The most detailed analyses of how alterations in HAT and
HDAC activity, and consequent epigenetic or signaling
effects, might contribute to chronic immune-mediated inflam-
matory diseases are found in studies of human airway
diseases, such as asthma and chronic obstructive pulmonary
disease (COPD). In both bronchial biopsies and alveolar
macrophages isolated from asthma patients, a significant
increase in HAT activity is detected [55,56]. A selective
decrease in HDAC1 expression is also observed in asthma
alveolar macrophages, corresponding with a decrease in
cellular HDAC activity. Decreased HDAC activity is in turn
associated with enhanced alveolar macrophage production of
proinflammatory granulocyte–macrophage colony-stimulating
factor, TNFα and IL-8 in response to lipopolysaccharide.
Similar changes in HAT and HDAC activity are not observed
in peripheral blood mononuclear cells from the same patients,
suggesting that alterations in reversible acetylation are
restricted locally to the site of inflammation [55].
In COPD patients, enhanced bronchial biopsy and alveolar
macrophage HAT activity does not occur, but a significant
reduction in total HDAC activity, and gene expression of
HDAC2, HDAC5 and HDAC8 but not of other class I/II
HDACs, is observed. The degree of local HDAC impairment
in COPD patients correlates with histone acetylation, IL-8
production and disease severity [57].
Evidence has also been provided that altered expression of
class III HDACs may contribute to chronic inflammation in
COPD. SIRT1 expression is decreased at both the mRNA
and protein levels in COPD bronchial biopsies and alveolar
macrophages. Oxidative stress may contribute to decreased
SIRT1 protein expression in COPD, as enhanced carbonyla-
tion and tyrosine nitration of SIRT1, mimicked by exposure of
SIRT1 to cigarette smoke extract, is observed [58]. A
potential role for sirtuins in autoimmunity is further suggested
by the observation that aged mice lacking the sirt1 gene
display deposition of autoimmune IgG1 antibodies in their liver
and kidneys, and show symptoms of diabetes insipidus [59].
Initial reports indicate that alterations in the balance of HAT
and HDAC activity may also contribute to perpetuation of
inflammation in RA. In a small study examining synovial tissue
obtained during joint replacement surgery of seven RA
patients, six osteoarthritis patients and control subjects, no
differences in HAT activity were observed [8]. HDAC activity
and the ratio of HDAC/HAT activity, however, were
significantly depressed in RA synovial tissue compared with
tissue from osteoarthritis patients and control patients.
Protein expression of HDAC1 and HDAC2 in whole synovial
tissue was lower in RA patients compared with osteoarthritis
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marked decrease in HDAC2 protein expression in RA
compared with osteoarthritis, particularly in synovial macro-
phages. These results led the authors to two conclusions
with important ramifications for future studies.
First, the data suggest an association between pathogenic
inflammatory processes in the RA synovium and reductions in
HDAC activity [8]. It is still uncertain whether the noted
changes in HDAC activity in RA synovial tissue are sufficient
to result in enhanced acetylation of histones or nonhistone
proteins, but – consistent with this possibility – we have
noted in a small study of four RA patients that acetylation of
cellular proteins in RA synovial tissue is most readily detected
within infiltrating macrophages (Figure 2). Within RA synovial
tissue, faint staining by anti-acetyl lysine antibodies is
detected throughout the tissue (Figure 2a), consistent with a
universal physiological role for histone and nonhistone protein
acetylation in regulating gene transcription and other cellular
activities. In a subset of cells, however, strong hyperacetyla-
tion is observed, localized to the nucleus (Figure 2a,b).
Doublestaining experiments performed on a small set of RA
patients suggest that this occurs most frequently in synovial
macrophages (CD68+, 48 ± 10%; CD163+, 39 ± 9%), the
same cell population within RA synovial tissue in which
depressed HDAC2 expression has been reported [8]. We
also frequently observe protein hyperacetylation in RA
stromal FLS (35 ± 7%), but rarely in synovial B lymphocytes
(22 ± 3%) and T lymphocytes (12 ± 2%). A pressing question
that remains to be determined experimentally is whether
these differences in HDAC activity and protein acetylation
can promote inflammatory gene transcription in RA.
A second important prediction put forth by Huber and
colleagues is that the observed decrease in HDAC activity
and expression in RA synovial tissue might preclude the
therapeutic application of HDACi in RA [8]. Important to this
is their observation that total HDAC activity is decreased by
approximately 75% in RA compared with normal synovial
tissue. One caveat to this interpretation of the data is that the
HDAC activity measured in this study was not normalized for
tissue cellularity or cell-type composition of the tissue. A
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Figure 2
Hyperacetylation of cellular proteins in rheumatoid arthritis synovial tissue. (a) Immunohistochemical staining of rheumatoid arthritis (RA) synovial
tissue with antibodies against acetyl-lysine (Ac) (upper panels) and control rabbit antibodies (lower panels): 100x (left panels) and 400x (right
panels) magnifications are displayed. (b) Immunofluorescent staining of RA synovial tissue (400x magnification) with anti-Ac antibodies (green)
alone (upper panel) or in combination with 4′,6-diamidino-2-phenylindole dihydrochloride staining (blue) (lower panel) showing localization to
cellular nuclei. (c) Representative immunofluorescent double staining of RA synovial tissue with anti-Ac antibodies (green) and antibodies against
cellular markers (red) for T lymphocytes (CD3), B lymphocytes (CD22), fibroblast-like synoviocytes (CD55), or synovial macrophages (CD68 and
CD163). (d) Quantification of protein hyperacetylation in specific synovial cellular subsets. Double stainings were performed on RA synovial tissue
and a minimum of 100 random cells positive for each CD marker assessed for hyperacetylation of nuclear proteins. Values represent the mean
percentage and standard error of the mean of cells positive for each marker displaying protein hyperacetylation from four RA patients. Samples
were obtained from patients fulfilling the American College of Rheumatology criteria for RA [98]. Detailed descriptions of materials and methods
used in these experiments have either been described elsewhere [60] or are available in Additional file 1.second caveat is that the tissue assessed was obtained from
patients at the time of joint replacement. Important differen-
ces in synovial cellular composition and cytokine profiles have
been detected between arthroscopic biopsies of RA patients
with active disease and specimens obtained during joint
replacement [60], underscoring the need for follow-up
studies of HDAC expression and activity in RA patients repre-
sentative of those who would be participating in clinical trials.
If the initial study results of Huber and colleagues can be
extended to active RA, this would certainly suggest that the
total availability of HDACs for inhibitory compounds would be
reduced. As yet, however, it is unclear whether HDAC1 and
HDAC2, reduced in RA, would be the relevant targets
responsible for potential anti-inflammatory effects of HDACi,
and whether the residual total HDAC activity present in RA
synovial tissue might still play an essential role in cellular
activation and survival. These unknown factors necessitate
extensive formal studies.
Histone deacetylases and glucocorticoid
treatment
Glucocorticoids (GCs) are invaluable therapeutic tools in the
treatment of many chronic inflammatory diseases, including
asthma and RA. Recent findings in the study of inflammatory
lung diseases demonstrate that HAT activity and HDAC
activity significantly impact upon the clinical efficacy of GC
therapy [15]. GC receptor-binding to GC response elements
in gene promoter regions can directly regulate gene
transcription, while at lower concentrations, GC also induce
GC receptor association with, and functional inhibition of,
transcription factors such as NFκB and activator protein 1.
GC-induced reduction of inflammatory gene transcription in
asthma patients is associated with the enhancement of HAT
activity and with the recruitment of HDAC2 to activated
NFκB complexes [55,61]. In contrast to asthma patients,
patients with COPD are relatively resistant to GC therapy,
and this could be in part due to depressed HDAC2
expression and activity [15,57]. Although HDAC2-deficiency
does not affect nuclear import or GC response element
binding of GC receptors, HDAC2-dependent deacetylation
of GC receptors is required for their association with NFκB.
The anti-inflammatory capacity of GC in asthma and COPD
alveolar macrophages can be restored either by over-
expression of HDAC2 or by theophylline-induced enhance-
ment of HDAC activity, indicating that strategies aimed at
restoring HDAC activity may enhance the efficacy of GC
therapy [55,62].
GC resistance in the treatment of RA is not as clearly defined
as in COPD [63]. More than 30% of RA patients, however,
have been estimated to demonstrate a decrease in respon-
siveness to GC therapy within 3 to 6 months from initiation of
treatment [64]. The reasons for this are currently unknown.
Suggested possibilities include decreased expression of GC
receptors, or changes in expression levels of chaperone and
co-chaperone proteins needed for GC receptor folding and
stability. Alternative contributions might be made by increased
expression of inflammatory transcription factors, expression of
alternatively spliced decoy GC receptors, and upregulation of
the multidrug resistance gene MDR1 [63]. In analogy to
COPD, we should consider whether depressed HDAC2
expression and activity in RA could also contribute to varia-
tion in patient responses to GC treatment. If this possibility
was to be substantiated, it would have two important clinical
implications. First, restoration of HDAC activity might
increase patient responsiveness to GC treatment, or might
allow effective utilization of lower doses of GC. Second, future
clinical trials specifically targeting HAT or HDAC activity to
treat RA would need to be conducted in the absence of
concomitant GC treatment, as effects of HAT/HDAC
modulators on GC responsiveness might introduce a signifi-
cant confounding factor to analyses of the studies.
In vitro, depsipeptide HDACi can induce upregulation of
MDR1 and its gene product P-glycoprotein in cancer cell
lines, conferring resistance to GC and chemotherapeutic
drugs [65,66]. Curiously, interactions between HDACi and
the  chemotherapeutic compound doxorubicin appear to be
extremely sensitive to the sequence of drug administration.
Pretreatment of cells with HDACi reduces subsequent doxo-
rubicin-induced apoptosis, while pretreatment with doxorubicin
sensitizes cells for HDACi-induced apoptosis. Given the
potential importance of these drug interactions in future clinical
trials, significant efforts need to be devoted to this issue in
preclinical analysis of HAT and HDAC modulators.
Histone deacetylase inhibitors in animal
models of inflammatory disease
While the studies above suggest that strategies aimed at
increasing HDAC activity could have therapeutic benefit in
RA, other lines of experimental analysis have instead provided
evidence that inhibition of HDAC activity should be pursued.
Early observations that HDACi could not only induce cell
cycle arrest and apoptosis in cancer cell lines, but also block
inflammatory cytokine production in these cells, provided a
rationale for experiments examining whether HDACi could be
used therapeutically to treat immune-mediated inflammatory
diseases. Compounds representing each of the chemical
classes of HDACi have been used successfully in prophy-
lactic and therapeutic protocols in multiple animal disease
models, including those for asthma, systemic endotoxic
shock, colitis, lupus, multiple sclerosis and graft versus host
disease [67,68].
A broad spectrum of HDACi has also shown potent
prophylactic and therapeutic effects in animal models of
arthritis. The first application of HDACi to the treatment of
arthritis was reported by Chung and colleagues [69]. Topical
ointments of phenylbutyrate and TSA were applied to rat
paws prior to induction of adjuvant-induced arthritis. Although
Available online http://arthritis-research.com/content/10/5/226
Page 7 of 13
(page number not for citation purposes)neither compound prevented arthritis onset, both compounds
inhibited paw swelling of treated paws, compared with
untreated and contralateral paws. Synovial inflammatory
infiltration, pannus formation and bone erosion were also
significantly reduced. The prophylactic effects of both phenyl-
butyrate and TSA were associated with local accumulation of
acetylated histone proteins in the tissue, an increase in
expression of the cell cycle inhibitors p16Ink4 and p21Waf1, and
depressed TNFα synthesis. Notably, HDACi treatment of
nonarthritic rats did not induce cell cycle inhibitor expression,
suggesting these compounds may preferentially affect cells in
the local inflammatory environment.
Another HDACi, the depsipeptide FK228, has displayed both
prophylactic and therapeutic benefits in rat adjuvant-induced
arthritis when administered intravenously [70]. Prophylactic
administration of the compound significantly reduced paw
swelling and completely blocked the development of bone
erosions. Although administration of FK228 after the onset of
arthritis failed to reduce paw swelling in this model, bone
erosion scores were reduced by almost 70%. FK228 was
also tested in the murine autoantibody-mediated model of
arthritis. A single-dose systemic administration of FK228,
administered after the clinical onset of arthritis, significantly
reduced joint swelling, synovial inflammation and bone
erosion [71]. The clinical benefits of FK228 were again
mirrored by an increase in synovial cell histone acetylation,
induction of synovial p16Ink4 and p21Waf1 expression, and
decreased TNFα synthesis.
SAHA and MS-275 have been examined in murine and rat
collagen-induced models of arthritis [72]. In mice, daily
subcutaneous injection of SAHA led to moderate dose-
dependent reductions in paw swelling, and production of IL-6
and IL-1β, but minimally reduced synovial infiltration and bone
destruction. MS-275, in contrast, provided almost complete
protection against arthritis, as assessed by the same para-
meters. In rats, both SAHA and MS-275 effectively reduced
arthritis severity and bone erosion, although MS-275 was
again more effective. When administered therapeutically in
rats, MS-275 prevented both a further increase in paw
inflammation, as well as the onset of bone erosions.
These studies together indicate that HDACi, irrespective of
their chemical classification, have the potential to alleviate
inflammation and to prevent joint destruction in arthritis. Of
particular interest to the clinical setting is the finding that a
subset of these compounds may be therapeutically useful in
established arthritis.
Effects of histone deacetylase inhibitors on
RA synovial cells
Attempts to extrapolate to RA the therapeutic benefits of
HDACi in animal models of arthritis, or the potential advan-
tages of enhancing HDAC activity, will require a thorough
analysis of the effects of HAT and HDAC modulation on
primary human immune and stromal cells relevant to RA,
preferably those derived from RA synovial tissue. As yet, there
is only a limited number of studies published assessing a few
of the cell populations considered important to the pathology
of RA.
T lymphocytes
Initial studies in T-cell responses indicate that HDAC
inhibition can reduce the activation of pathogenic effector
T cells and of memory T cells, while enhancing regulatory
T-cell function. Incubation of healthy donor peripheral blood
mononuclear cells with TSA reduces phytohemagglutinin and
toxic shock syndrome toxin 1-induced production of T-helper
type 1 cytokines, such as IFNγ, while enhancing T-helper type
2 cytokine production [73]. TSA similarly normalizes T-helper
type 1-skewed cytokine production in mitogen-stimulated
T cells from systemic lupus erythematosus patients [74].
However, SAHA, another HDACi, is ineffective in blocking
anti-CD3-induced human T-cell IFNγ production, as well as in
vitro and  in vivo alloantigen-driven murine T-cell activation
and proliferation [52,75].
Intriguing evidence has recently emerged that HDAC activity
can also modulate the generation and function of anti-
inflammatory thymic-derived natural regulatory T lymphocytes
[76]. Systemic treatment of mice with TSA increases the
frequency of natural regulatory T cells. Either incubated with
TSA  in vitro or isolated from TSA-treated mice, regulatory
T cells display elevated FoxP3 expression and have enhanced
suppressive function in vitro. FoxP3 is acetylated under these
conditions, promoting FoxP3 association with the IL-2
promoter. HDAC9, prominently expressed in regulatory
T cells, appears to be responsible for inactivating FoxP3, and
regulatory T cells from HDAC9 knockout mice are increased
in numbers and suppressive capacity [76]. It is as yet unclear
whether human regulatory T cells are similarly regulated by
HDAC9 activity, but together these studies suggest that
HDACi effects on T-cell-dependent immune responses are
dependent upon the mode of T-cell activation, T-cell
differentiation status or lineage commitment, and on the
HDACi used.
Monocytes
HDACi have been most extensively studied in monocytes and
monocyte-derived cell lineages. SAHA inhibits release of
TNFα, IL-1β, IL-12 and IFNγ by lipopolysaccharide-stimulated
human monocytes [75]. The anti-inflammatory effects of
SAHA are selective, as IL-8 production remains unaffected.
Moreover, while induction of TNFα, IL-12 and IFNγ
production is inhibited at the transcriptional level, defects in
IL-1β release are due to blocks in cytokine exocytosis [31].
The effects of SAHA on monocyte cytokine production and
release are mimicked by other class I/II HDACi (TSA and
ITF2357), the class I-selective HDACi HC-toxin, and the
HDAC6-specific HDACi tubacin [31]. In all cases, HDACi
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cause monocyte apoptosis, providing evidence that anti-
inflammatory effects of HDACi can be achieved in the
absence of general cellular toxicity. Murine bone marrow-
derived monocyte differentiation into macrophages is un-
affected by HDACi, but these compounds suppress differen-
tiation into osteoclasts [77]. In vitro, this may be a result of
inhibition of receptor activator of NFκB ligand-induced NFκB
transcriptional activity; and in vivo, via induction of IFNβ
production by synovial cells [70].
Macrophages and dendritic cells
Studies of asthma and COPD alveolar macrophages demon-
strating that decreased HDAC expression and activity are asso-
ciated with enhanced lipopolysaccharide-induced granulocyte–
macrophage colony-stimulating factor, TNFα and IL-8 release
might predict that HDACi would also enhance macrophage
inflammatory responses [55,57]. While HDACi block restoration
of alveolar macrophage GC responsiveness induced by
theophylline or HDAC overexpression [62,78], experiments
directly examining the influence of HDACi on asthma and
COPD alveolar macrophage activation have not been reported.
In contrast, the pan-HDACi LAQ824 selectively inhibits mono-
cyte-derived macrophage and dendritic cell production of
monocyte/macrophage/dendritic cell chemokines and chemo-
kine receptors, as well as the production of costimulatory
molecules, cytokines and chemokines required for T-helper type
1 T-cell recruitment and activation [79].
Fibroblast-like synoviocytes
Stromal FLSs are the only cell population isolated from RA
synovial tissue in which the effects of HDACi have been
studied. Incubation of RA FLS with FK228 induces cell cycle
arrest, associated with enhanced expression of the cell cycle
inhibitor p16Ink4a and acetylation of the p16Ink4a promoter
region [71]. Treatment of FLS with either FK228 or TSA fails
to induce apoptosis, but TSA can sensitize FLS to TRAIL-
induced apoptosis [71,80]. This suggests that HDACi might
be particularly effective in targeting FLS proliferation or
survival at the site of inflammation. Supporting this, while TSA
and phenylbutyrate induce cell cycle arrest in FLS obtained
from healthy rats and arthritic rats, cell cycle arrest is
reversible in normal FLS following drug removal, but main-
tained in FLS derived from arthritic joints [69].
It will be of interest to examine the effects of HDACi on FLS
cytokine production, as these compounds have demonstrated
both inflammatory and therapeutic effects on (model stromal
cells or) stromal cells derived from other immune-mediated
inflammatory diseases. In SV-40-transformed bronchial epi-
thelial cell lines – often used as models in asthma and COPD
studies – TSA alone, or in synergy with oxidative stress, can
induce IL-8 production [81]. In fibroblasts obtained from
biopsies of patients with systemic sclerosis, TSA reduces
transforming growth factor beta, IL-4 and platelet-derived
growth factor-induced collagen synthesis [82].
Endothelial cells and angiogenesis
Angiogenesis in the synovial membrane contributes to
synovitis and disease progression in RA by increasing
inflammatory white blood cell access to affected joints,
sustaining the nutritional requirements of invasive hyper-
plastic synovial tissue and stimulating osteoclast-mediated
bone resorption [83]. A potential role for HDACs in regulating
angiogenesis in chronic inflammatory diseases has not been
addressed experimentally, but can be predicted based on
numerous studies from tumor biology and the characteri-
zation of genetically modified mice.
HDACi display inhibitory effects on angiogenesis in both in
vitro and  in vivo tumor models [84-90]. These effects
probably result from both epigenetic influences and acetyla-
tion of hypoxia-inducible factor 1 alpha (HIF-1α) – acetylation
of HIF-1α promotes ubiquitination and degradation of this
critical transcriptional regulator of proangiogenic and anti-
angiogenic factors [86,87,91]. In these tumor models, class II
HDACs – rather than class I HDACs – appear to coordinate
angiogenesis. In human renal carcinoma cells, inhibition of
class I HDAC activity is insufficient to suppress HIF-1α, but
silencing of class II HDAC4 and HDAC6 can induce HIF-1α
acetylation, reducing both HIF-1α expression and activity [87].
Cellular and molecular mechanisms underlying HDAC-
dependent regulation of angiogenesis have also been
investigated in primary endothelial cells. FK228 is a potent
inhibitor of hypoxia-induced endothelial cell proliferation,
migration and adhesion [88]. In vascular endothelial growth
factor (VEGF)-induced angiogenesis in vivo models, TSA and
SAHA inhibit angiogenesis and vasculogenesis – accom-
panied by suppression of VEGF receptors 1 and 2, and
induction of the VEGF competitor semaphorin III [89].
Furthermore, valproic acid and TSA block endothelial cell
nitric oxide signaling by suppressing expression of endothelial
nitric oxide synthase [90,92].
Genetic studies have demonstrated that HDAC3 and
HDAC7 play an important role in angiogenesis and the
maintenance of vascular integrity. Elevated levels of HDAC3
are detected in the walls of blood vessels during embryo-
genesis in mice, and HDAC3 plays an essential role in VEGF-
induced embryonic stem cell differentiation into endothelial
cell lineages in vitro [93]. In mice lacking HDAC7 expression,
endothelial cell–cell contacts are disrupted, leading to
dilation and rupture of blood vessels, and embryonic lethality
[94]. The silencing of HDAC7 in human endothelial cells
results in cellular alterations in morphology, migration and
capacity to form capillary tube-like structures. HDAC7
knockdown induces strong upregulation of platelet-derived
growth factor B and its receptor, which is at least partially
responsible for the inhibition of endothelial cell migration [95].
Together, these studies raise the possibility that targeting
specific HDACs may be useful in preventing contributions of
angiogenesis to inflammation and joint destruction in RA.
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Effects of HDACi on cartilage and collagen catabolism by
chondrocytes may also contribute to protection of animals
from joint destruction in experimental models of arthritis.
Treatment of primary human chondrocytes with either TSA or
phenylbutyrate inhibits gene and protein induction of matrix
metalloproteinases and aggrecan-degrading enzymes
(ADAMTS) induced by IL-1β and oncostatin M [96]. TSA and
butyric acid also block nitric oxide, prostaglandin E2, and
proteoglycan release in TNFα-stimulated, IL-1β-stimulated
and IL-17-stimulated osteoarthritis chondrocytes or cartilage
explants [97], indicating that inflammatory disease does not
generally render chondrocytes insensitive to HDACi.
These initial studies together indicate that HDACi generally
possess anti-inflammatory (or otherwise therapeutic) effects
in vitro on many of the cell populations that contribute to
synovitis and disease progression in RA. In terms of
translational cell biology, it will be important to understand the
effects of modulating expression and activity of specific
HDACs in these cell populations. Additionally, more effort is
needed in identifying appropriate biochemical and cellular
biomarkers of compounds modulating HDAC activity, both in
vitro and in therapeutic treatment of arthritis in animal models.
Conclusions
Temporal and balanced regulation of HAT and HDAC activity
is required for an effective but self-limiting immune response.
HAT activity allows transcription factor access to gene
promoter regions, and modulates transcription factor stability,
DNA binding and transcriptional activity. HDAC activity can
subsequently modify transcription factor activity, prevent
expression of proapoptotic genes, and eventually terminate
transcription following deacetylation of histones.
While studies in human immune-mediated inflammatory
diseases indicate that strategies aimed at decreasing HAT
activity and restoring HDAC activity may benefit the treatment
of RA, in vitro experimental data and animal arthritis models
suggest promise for HDACi in the clinic. Are these strategies
mutually exclusive? Integrating the available data into a
testable model suggests not (Figure 3). If initial studies in RA
synovial tissue can be extended to larger patient cohorts, and
if depressed HDAC activity contributes to localized synovial
inflammation, then we might predict that an enhanced ratio of
HAT activity to HDAC activity may sensitize cells to
inflammatory gene transcription via chromatin remodeling,
may increase the DNA binding and activity of transcription
factors, and may increase cellular resistance to GC treat-
ment. Residual HDAC activity, however, would be sufficient
to maintain transcription factor activity and prevent the
targeting of genes that induce cell cycle arrest or apoptosis.
Restoration of HDAC activity could either decrease inflam-
matory gene transcription or enhance patient responses to
GC treatment. If results from animal models of arthritis and in
vitro studies of cells isolated from RA patients can be
extended to RA synovial tissue, however, then residual HDAC
activity may be critical for maintaining pathology. In this case,
further depression of HDAC activity by HDACi might inhibit
transcription factors required for inflammatory gene
production, and instead may stimulate transcription of genes
involved in cell cycle arrest and apoptosis.
Several pressing issues need to be addressed as we
proceed with the preclinical evaluation of HAT and HDAC
modulators in RA. Of immediate importance is determining
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Figure 3
Potential pathological and therapeutic consequences of modulating
histone deacetylase activity in rheumatoid arthritis. Depressed histone
deacetylase (HDAC) activity relative to histone acetyl transferase
(HAT) activity in rheumatoid arthritis (RA) synovial tissue might
promote chromatin relaxation and activation of inflammatory
transcription factors (TF). Moreover, depressed HDAC activity may
decrease patient responsiveness to glucocorticoid (GC) treatment.
The therapeutic application of HDAC agonists may decrease
inflammation by promoting chromatin condensation and/or
deacetylating TF at sites required for DNA binding. Additionally,
patients may respond better to GC therapy. Therapeutic application of
HDAC inhibitors might demonstrate clinical benefits by preventing
deacetylation of TF at sites required for their activation, or inducing
transcription of genes promoting cell cycle arrest or apoptosis. HDAC
inhibitors, however, might render RA patients refractory to concomitant
GC therapy. Ac, acetylation.whether or not there is a relationship between changes in
synovial tissue HAT activity and HDAC activity with inflam-
mation in RA – and if so, whether this relates to changes in
acetylation of histone or nonhistone proteins. We also need
to examine the effects of HDAC modulators on the activation
and survival of specific RA synovial cell populations. By
extension, biochemical and cellular biomarkers most relevant
to modification of HAT activity or HDAC activity in RA remain
to be identified. The determination of which HDACs are
important for activation and survival of these cell populations
will shed light on the molecular mechanisms of drug activity,
and will indicate whether pan-HDACi or the targeting of
specific HDACs will be most useful in the clinical setting.
Finally, in eventually moving new compounds to the clinic, no
studies have been performed examining the relationship
between HAT and HDAC activity and RA patient responses
to GC therapy. Given the intimate interaction of GC and
acetylation in inflammatory lung diseases, this may be
important in the future design of clinical trials.
Initial studies have certainly generated hope that modulating
HDAC activity may provide a new therapeutic tool in the
treatment of RA. But for the time being, until we more fully
expose the contributions of protein acetylation and
deacetylation to the pathobiology of RA, and the therapeutic
potential of HDACi, it might be prudent to leave our HATs on.
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